New SEC Form D filing

Jasper Therapeutics, Inc., 2026-08-05

A new SEC Form D private-offering notice from Redwood City, CA, a $131,999,611 filer-stated offering target in Biotech. The source filing is one click away.

What this filing says

Jasper Therapeutics, Inc. site↗ Verified via SEC Form D

Clinical stage biotech developing briquilimab, an anti-KIT antibody depleting mast cells to treat chronic urticaria and allergic asthma

Filed 2026-08-05Filed to raise $131,999,611First money in 2026-07-21Raised so far $131,999,611HQ (as filed) Redwood City, CASector Biotech web-verified against the company’s own siteStage (inferred) LateCall status Call-ready
Source linked the Form D on EDGAR↗Website verified jaspertx.com↗Named in the filing 10 executives & directors
Open this row on the live feed →More new filings in California →More Biotech filings →

This is a public SEC Form D private-offering notice, the filer's own statement to the SEC. Amounts are offering targets, not confirmed closes. Takeoff Radar pulls Form D nightly from EDGAR and links every filing to its source.

Other Form D filings from the same week

each with its own page and its own EDGAR source